Intra-Cellular Therapies (ITCI) PT Raised to $71 at Goldman Sachs
Tweet
Share
E-mailGet Alerts ITCI Hot Sheet
Price: $73.12 -1.2%
Rating Summary:
17 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
17 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
Goldman Sachs analyst Corinne Jenkins raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $71.00 (from $64.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intra-Cellular Therapies (ITCI) PT Raised to $107 at Canaccord Genuity
- HSBC Downgrades Anglo American Platinum Limited (AMS:SJ) (ANGPY) to Reduce
- Compass Minerals International (CMP) PT Lowered to $15 at Deutsche Bank
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Goldman Sachs, The Children's Investment Fund (TCI)Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
